drug
lonafarnib
Marketedupdated 3mo agoby Sentynl Therapeutics Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lonafarnib
- phase3Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
- phase2Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
- phase2Titrating-Dose of Lonafarnib in Combination With Ritonavir
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 20, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 26, 2029method-of-use (U-3070)US 78385312.9y
- Jul 26, 2029method-of-use (U-3070)US 78385312.9y
FDA exclusivities (2)
- Nov 20, 2027ODE-324Orphan Drug (7y)1.3y
- Nov 20, 2027ODE-324Orphan Drug (7y)1.3y
News(1)
- Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drugSentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.fiercebiotech · 7d ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that